We measured the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 (VLDL apoB) using a stable isotope gas-chromatography mass-spectrometry method in six patients with non-insulin-dependent diabetes mellitus (NIDDM) (four males, two females, age 57.5+2.2years (mean + SEM), weight88.2 + 5.5 kg, glycated haemoglobin (HbA1) 8.5 _+ 0.5 %, plasma total cholesterol concentration 5.7 + 0.5 mmol/1, triglyceride 3.8 + 0.9 mmol/1, high-density lipoprotein (HDL) cholesterol 1.0 + 0.1 mmol/1) and six non-diabetic subjects matched for age, sex and weight (four males, two females, age 55.7 + 2.8 years, weight 85.8 + 5.6 kg, HbA 1 6.5 + 0.1%,plasma total cholesterol concentration 5.7 +_ 0.5 mmol/1, triglyceride 1.2 + 0.1 mmol/1, HDL cholesterol L4 + 0.1 mmol/1). HbA1, plasma triglyceride and meval0nic acid (an index of cholesterol synthesis in vivo) concentrations were significantly higher in the diabetic patients than in the non-diabetic subjects (p = 0.006, p = 0.02 and p = 0.004, respectively). VLDL apoB absolute secretion rate was significantly higher in the diabetic patients compared with the non-diabetic subjects (2297 + 491 vs 921 + 115 rag/day, p < 0.05), but there was no significant difference in the fractional catabolic rate of VLDL apoB. There was a positive correlation between VLDL apoB secretion rate and (i) fasting Cpeptide (r = 0.84, p = 0.04) and (ii) mevalonic acid concentration (r = 0.83, p < 0.05) in the diabetic patients but not in the non-diabetic subjects. There was also a significant positive association between plasma mevalonic acid and plasma C-peptide (r = 0.82, p < 0.05) concentrations in the diabetic patients. We conclude that in NIDDM, there is increased hepatic secretion of VLDL apoB which may partly explain the dyslipoproteinaemia seen in this condition. We suggest that increased secretion of this apolipoprotein may be a consequence of resistance to the inhibitory effect of insulin on VLDL apoB secretion. Insulin resistance may also be the mechanism by which cholesterol synthesis, a regulator of apoB secretion, is increased in NIDDM. [Diabetologia (1995) 38: 959-967] 
cant difference in the fractional catabolic rate of VLDL apoB. There was a positive correlation between VLDL apoB secretion rate and (i) fasting Cpeptide (r = 0.84, p = 0.04) and (ii) mevalonic acid concentration (r = 0.83, p < 0.05) in the diabetic patients but not in the non-diabetic subjects. There was also a significant positive association between plasma mevalonic acid and plasma C-peptide (r = 0.82, p < 0.05) concentrations in the diabetic patients. We conclude that in NIDDM, there is increased hepatic secretion of VLDL apoB which may partly explain the dyslipoproteinaemia seen in this condition. We suggest that increased secretion of this apolipoprotein may be a consequence of resistance to the inhibitory effect of insulin on VLDL apoB secretion. Insulin resistance may also be the mechanism by which cholesterol synthesis, a regulator of apoB secretion, is increased in NIDDM. [Diabetologia (1995) 38: 959-967] Non-insulin-dependent diabetes mellitus (NIDDM) is associated with an increased risk of macrovascular disease [1] which may be due to abnormalities in lipid and lipoprotein metabolism [2] . The mechanism underlying diabetic dyslipoproteinaemia is not, however, fully established but may be closely linked with hyperinsulinaemia [3] . Previously, increased circulating insulin was assumed to act directly on the liver stimulating very-low-density lipoprotein (VLDL) secretion in NIDDM and contributing to hypertriglyceridaemia [4] . This concept was supported HbA1, glycated haemoglobin; M, male; F, female by in vivo work showing a significant positive correlation between hyperinsulinaemia and enhanced secretion of VLDL by the liver in diabetes [5] . More recently, insulin administration to human subjects has been shown to decrease VLDL secretion [6, 7] and has led to the hypothesis that in NIDDM, there is loss of sensitivity to the normal insulin-mediated suppression of VLDL secretion [8, 9, 10] . Studies examining the metabolism of apoB, the structural protein of VLDL and a determinant of plasma lipid and lipoprotein concentrations [9] , have also supported the proposed inhibitory role of insulin. Both experimental [11, 12] and in vivo [13] studies have demonstrated that insulin inhibits VLDL apoB secretion from the liver in the normal insulin sensitive state. However, whether hepatic secretion of this apolipoprotein is increased in the insulin resistant state of NIDDM remains unresolved [14] . Hitherto, results of studies examining VLDL apoB secretion in NIDDM have been conflicting [15] [16] [17] [18] , possibly due to small sample size and differences in the study protocols or patient's characteristics. In addition, these studies used radioisotopic techniques which may introduce methodological difficulties associated with exogenous labelling of VLDL apoB [19, 20] . Stable isotope methods using gas-chromatography massspectrometry (GCMS) are a relatively new approach for determining the kinetics of apoB metabolism [21] and may overcome some of the potential drawbacks associated with radioactive techniques. GCMS may also be used to measure plasma mevalonic acid (MVA) concentration [22] , a measure of in vivo cholesterol synthesis [23] . Studies in rat liver slices [24] and more recently in vivo [25] [26] [27] have demonstrated that cholesterol biosynthesis regulates VLDL apoB secretion. In addition, studies of Hep G2 cells have shown that in response to a fatty acid challenge, apoB secretion was increased as a result of enhanced cholesterol synthesis [28] . In vivo work has also shown that increased fatty acid supply to the liver following feeding stimulates VLDL apoB secretion [29] . Since there is increased fatty acid supply to the liver in NIDDM [30] , it is possible that the effects of insulin resistance on hepatic secretion of apoB are mediated through increased intrahepatic cholesterol synthesis.
The main aim of this study was to employ a stable isotope technique to test the hypothesis that in NIDDM, hepatic secretion of VLDL apoB is increased. A secondary aim was to explore the associations between hepatic VLDL apoB secretion and plasma MVA, insulin and C-peptide concentrations.
Subjects and methods
Subjects. Six patients with NIDDM (four males, two females) who were attending the diabetic clinic volunteered for the study. Diabetes was diagnosed according to the World Health Organisation criteria and had been present for a minimum of 2 years. All the patients were treated with a modified diet (45 % carbohydrate, 35 % fat, 20 % protein) alone and had a glycated haemoglobin less than 10.5 %. Six non-diabetic subjects matched for age and sex were also studied. They had been consuming a weight-maintenance (isocaloric) diet prior to the study. The subjects' clinical and biochemical characteristics are shown in Tables 1 and 2 . None of the subjects had a primary lipid disorder, proteinuria, hypothyroidism, abnormal liver enzymes or were taking drugs known to affect lipid metabolism. All subjects provided informed written consent and Experimental protocol (Fig. 1 ). All subjects were admitted to a metabolic ward at 08.00 hours after a 12-h fast. They were studied in a semi-recumbent position and allowed to consume only water. An indwelling cannula was placed in a superficial vein of each antecubital fossa at the beginning of the study. 1-13C -leucine (Tracer Technologies, Somerville, Mass., USA, 15 mg/ ml, 13C enrichment 99 %), was administered as a primed (1 mg/kg), constant (1 rag. kg -1. h -1) infusion via the right cannula for 8 h. Blood samples were collected from the left cannula into 10 ml tri-potassium EDTA (0.34mol/1) at baseline and at 30-rain intervals during the study. Blood samples (5 ml) were collected into lithium heparin (15 units/ml blood) at baseline and at 60-min intervals to determine 13C enrichment of plasma c~-ketoisocaproic acid (c~-KIC), the deamination product of leucine which provides a measure of intracellular leucine enrichment [31] . At the beginning of the study, 10 ml blood was collected into an EDTA (0.34mol/1) tube to measure plasma total cholesterol (TC), HDL cholesterol, triglycerides (TG), glucose, HbA1, insulin and MVA concentrations and apolipoprotein E phenotype. Also, 10 ml of blood was collected into a plain tube to measure non-esterified fatty acids (NEFA) and glycerol concentrations and 2 ml of blood was collected into an EDTA tube containing 100 ~1 of trasylol to measure C-peptide concentration.
Isolation and measurement of isotopic enrichment of VLDL apoB. The methods have been fully described elsewhere [32] and are summarised below. All EDTA samples were initially stored at 4 ~ and analysed within 24 h of collection. A 2-ml aliquot of plasma was overlayered with 3 ml of sodium chloride density solution (d = 1.006 kg/l) and ultracentrifuged for 16 h at 147,000 g. The supernatant containing VLDL was aspirated after separation from the infranatant by tube-slicing. ApoB within the VLDL fraction was precipitated by the tetramethylurea method, a technique that is highly specific for isolating apo B-100 (> 97 %) [33, 34] . The precipitate was then delipidated, dried under oxygen-free nitrogen and then hydrolysed with 6 mol/1 hydrochloric acid for 24 h at 115~ After reconstitution in 50 % acetic acid, the amino acids were eluted by cation-exchange chromatography using 2 ml of 3tool/1 ammonia. The eluted amino acids were lyophilised and stored at -20~ until derivatisation. The samples were derivatised by the addition of 100 91 acetonitrile and 100 ~1 N-methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide to form the bis (tert-butyldimethylsilyl) derivative. Excess reagent was removed and the derivative reconstituted in 200 ~1 decane for GCMS analysis. Isotopic enrichment was determined by selected ion monitoring at m/z of 303 and 302 using a Gas Chromatograph-Mass Spectrometer (VG Biotech TRIO-2, VG Biotech Ltd., Altringham, Cheshire, UI<2), employing electron-impact ionisation. 13C/12C leucine area ratios were corrected for the standard curve of observed vs expected isotopic enrichment of stock solutions of nC and 13C leucine (10 9g/ ml) prepared for GCMS analysis as described above. Plasma samples of c~-KIC were stored at -70~ prior to extraction and on thawing were deproteinised using ethyl alcohol. After drying the supernatant and adding 1,2 phenylenediamine and hydrochloric acid, the keto-acids were extracted with ethyl acetate and dried over sodium sulphate. The dried residue was derivatised with 100 gl of pyridine and 50 ~1 of NO-bis (trimethylsilyl) trifluoroacetamide and 1% trimethylchlorosilane, and heated at 120~ for 45 min to form the quinoxalinol-tri-methyl silyl derivative. The sample was then prepared for GCMS analysis as for leucine. Isotopic enrichment was determined by selected ion monitoring at m/z 233 and 232 (GCMS analysis: Hewlett Packard 5890A, Bracknell, Herts., UK) using electron impact ionisation. Leucine and c~-KIC enrichment were calculated using the formula [35] :
where Rt is the 13C/nC ratio at time t and R 0 is 13C/12C ratio at baseline prior to the infusion of 1-13C leucine. Analytical precision of the method (CV), assessed by taking replicate samples ( x 5) at two time points in six of the studies, was less than 8 % for isotopic enrichment (E) of leucine and c~-KIC. Quantification of VLDL apoB and other analytes. VLDL was pooled from three successive hourly samples and VLDL apoB concentration was determined in each pooled sample using a modified Lowry method, as described previously [36] .
The mean concentration of apoB in the three pooled VLDL samples per study was taken for purposes of calculating VLDL apoB secretion rate. Plasma TC and TG concentrations were measured by an enzymatic method (Boehringer Mannheim, Mannheim, Germany) using a Cobas-centrifugal analyser (Roche, Welwyn Garden City, Herts., UK). HDL cholesterol was separated by precipitation of apoB containing proteins with dextran sulphate/magnesium chloride and measured enzymatically. Plasma glucose was measured by a glucose oxidase technique (Yellow Springs 23 AM glucose analyser, Yellow Springs, Ohio, USA). HbA 1 was measured by a high-performance liquid-chromatography method (interassay CV 8 %). Plasma immunoreactive insulin and C-peptide concentrations were measured in duplicate by double antibody radioimmunoassay techniques, interassay CV 6 % and 5 %, respectively. Plasma NEFA and glycerol concentrations were measured by an enzymatic method using commercially available kits (NEFA: Randox Laboratory, Crumlin, Co. Antrim, N. Ireland, UK), interassay CV 3.6 %; (glycerol: Wako Laboratory, Neuss, Germany), interassay CV 3.2 %. Plasma MVA concentration was measured by capillary gas chromatography-electron capture mass spectrometry using a modified version [37] of the method described by Scoppola et al. [22] , (Sigma, Poole, Dorset, UK and DB5 capillary GC column, 30m, Jones Chromatography, Mid-Glamorgan, UK), interassay CV 6.7 %. Apolipoprotein E phenotype was determined by isoelectric focusing [38] .
Calculation of VLD L apoB secretion rate. The fractional secretion rate (FSR) of VLDL apoB (pools/day) was determined by fitting a monoexponential function to the enrichment data, [35] :
where F is the precursor enrichment, d is the intrahepatic delay time, k is the FSR of VLDL apoB and Z (t) is the tracer:tracee mass ratio at time t calculated as, [35] :
where E(I) is the;isotopic enrichment of the infusate. The were derived from the plot of Z(t) of VLDL apoB vs time data. Precursor enrichment (F) was estimated as the plateau isotopic enrichment from Z(t) of c~-KIC vs time data [39] . The curve fit for each set of data was accepted after finding the minimum value for the standard error (SE) of the estimated parameter (P) expressed as a percentage of R Mean values of [SE/P x 100] for accepted curve fits were less than 9 % for F and d, and less than 16 % for k. The absolute secretion rate (ASR) of VLDL apoB was calculated as the product of FSR and pool size. Pool size was determined as the product of plasma volume and VLDL apoB concentration. The plasma volume was measured at the midpoint of each study by a standard isotopic dilution technique using 1251 albumin [40] .
Statistical analysis
Skewed variables (plasma and VLDL TG concentration, VLDL apoB concentration, pool size and ASR) were examined after log transformation. Since patients within each group were individually matched, Student's paired t-test was used to compare clinical, biochemical and kinetic characteristics as decribed by Altman [41] . Associations between VLDL apoB ASR and other variables were examined using simple linear regression methods. Variables that were significantly associated with apoB secretion rates (p < 0.05) following univariate analysis were then entered into multiple linear regression analysis in order to assess their relative association with VLDL apoB ASR. Table 1 shows that the patients and non-diabetic subjects were well matched for age, weight and sex. The diabetic patients had significantly higher plasma glucose, HbA 1, TG, MVA concentrations, VLDL TG concentration and VLDL TG/apoB ratio than the non-diabetic subjects (Tables 1, 2 ). Figure 2 demonstrates that steady-state isotopic enrichment of VLDL apoB was reached more rapidly in the nondiabetic subjects compared with the diabetic patients; in both groups, there was no significant difference between the isotopic enrichment of VLDL apoB and c~-KIC measured at 420 and 480 min. He- patic VLDL apoB secretion rate, expressed as mg/ day or mg-kg -1 9 day -1 was significantly higher in the diabetic group compared with the non-diabetic group (p < 0.05) ( Table 3 ). The fractional catabolic rate (equivalent to fractional secretion rate at steady state) was not significantly different between the two groups (Table 3) . Univariate regression analysis showed a positive correlation between log VLDL apoB secretion rate (mg/day) and fasting C-peptide (r = 0.84, p--0.04) and MVA (r = 0.83, p < 0.05) concentrations in the diabetic patients (Fig. 3) ; consistent with a significant positive association between plasma C-peptide and MVA concentrations (r=0.82, p<0.05) in this group. The association between VLDL apoB ASR and TG and VLDL TG almost reached conventional statistical sigificance (p = 0.06) in the diabetic patients. There was no significant association between these variables in the non-diabetic group. In addi- 
Results

Discussion
This is the first study using stable isotopes to demonstrate increased hepatic secretion of VLDL apoB in NIDDM patients. The study also suggests that increased secretion of apoB may be due to insulin resistance, consistent with our findings in obese subjects [42] . Our results show that enhanced cholesterol synthesis is a feature of insulin resistance and that it may play an important role in increasing hepatic secretion of apoB in NIDDM. Hitherto, studies examining apoB secretion in NIDDM patients have used radioactive tracers and the findings have not been consistent. Kissebah et al. [15] showed that VLDL apoB secretion was increased in both normolipidaemic and hyperlipidaemic patients. In contrast, Taskinen et al. [16, 17] and Howard et al. [18] found normal VLDL apoB secretion rates in hyperlipidaemic diabetic patients. These studies exogenously labelled VLDL with 131iodine, a technique that may give rise to methodological errors: chemical modification during harvesting of VLDL that may alter its metabolism in vivo [19] , non-uniform labelling of all subspecies of VLDL resulting in lower estimates of apoB transport [20] and VLDL apoB fractional secretion rates are not directly measured but inferred indirectly from fractional catabolic rates. In addition, the diabetic groups were not individually matched with control subjects for age, sex and weight which may affect interpretation of the findings. These potential meth, odological errors and differences in experimental protocols and patients' characteristics may explain the discrepancies in apoB secretion rates.
When interpreting our data, several assumptions were made. Monoexponential analysis incorporating a delay function was used to model the isotopic enrichment data, a method which has been used previously to examine VLDL apoB metabolism [21, 43] . The enrichment of plasma a-KIC was used as a measure of intracellular leucine enrichment. This analysis assumes that steady-state isotopic enrichment of the precursor pool is constant at the beginning of the study. Although in practice, isotopic enrichment is zero at the beginning of each study, Figure 2 shows that steady-state enrichment of c~-KIC with 13C occurred rapidly, within 60 min of tracer infusion. Moreover, fractional secretion rates calculated by monoexponential analysis have been shown not to differ significantly from results using a more complex multicompartmental model in normolipidaemic subjects [21] . This analysis also assumes that plasma c~-KIC is in equilibrium with intrahepatic c~-KIC and that plasma a-KIC (and hence intrahepatic c~-KIC) reflects the enrichment of hepatic leucine amino acyl tRNA, the direct precursor of apoB. These two assumptions appear to be supported by experimental work in dogs demonstrating that there is equivalent enrichment of 13C in leucine from hepatic tissue and plasma c~-KIC [44] . Moreover, in vivo studies confirm the isotopic enrichment of plasma a-KIC and VLDL apoB to be highly correlated at steady state [34, 45] .
In the non-diabetic state, acute hyperinsulinaemia decreases VLDL apoB secretion in experimental [11, 12] and in vivo [13] studies. Assuming that this effect of insulin may occur in the chronic hyperinsulinaemic state, this study suggests that in NIDDM the resistance to the inhibitory effect of insulin on apoB secretion causes increased secretion of this apolipoprotein by the liver. This is supported by the positive association between C-peptide concentration and VLDL apoB secretion rate in the diabetic subjects. Since raised C-peptide concentration is a relatively insensitive index of insulin resistance in NIDDM, this association may have been even stronger had we used glucose disposal rates during an insulin clamp procedure to assess insulin resistance [46] . We hypothesize that this enhanced secretion of apoB in NIDDM may be stimulated by increased intrahepatic cholesterol synthesis. Plasma MVA levels pro-vide a measure of in vivo cholesterol synthesis [23] and studies on rat liver slices [24] , normolipidaemic adults [25] and patients with cholesterol ester storage disease [26, 27] have demonstrated that rates of cholesterol synthesis and VLDL apoB secretion are correlated. Increased hepatic cholesterol availability from an exogenous source may also increase apoB secretion, as evidenced by in vitro work [47] and our recent observation in patients with heterozygous familial hypercholesterolaemia [32] . In keeping with these findings, the present study demonstrated a positive association between plasma MVA concentration and VLDL apoB secretion in the diabetic group. Our data also showed that plasma MVA concentration was higher in the diabetic subjects which may be explained in part by differences in apoE phenotype; patients with the apo E2 allele have been shown to have higher rates of cholesterol synthesis than those patients with the E4 allele whilst cholesterol synthesis in apo E3E3 homozygotes lies between these two rates [48] . Since there was a positive association between plasma MVA and C-peptide concentrations, cholesterol synthesis may be increased also, as a result of insulin resistance. In contrast to our findings, others have reported that acute hyperinsulinaemia induced by using an insulin clamp in IDDM subjects [49] , or consumption of a carbohydrate meal by IDDM and NIDDM subjects [50] stimulated cholesterol synthesis; they studied lymphocytes, however, which may not accurately reflect whole body cholesterol synthesis. In NIDDM, increased hepatic uptake of circulating NEFA due to insulin resistance [30] could have also increased VLDL apoB secretion, possibly by stimulating cholesterol synthesis. This is supported by studies in Hep G2 cells showing that in response to a fatty acid challenge, apoB secretion was increased as a result of enhanced cholesterol synthesis [28] . In addition, increased fatty acid supply to the liver following feeding stimulated VLDL apoB secretion in normolipidaemic adults [29] . The stimulatory effect of increased fatty acid availability has received further support recently from studies examining the addition of exogenous VLDL to Hep G2 cells in which fatty acid availability was the critical factor associated with increased apoB secretion [51] . Although we did not find an association between plasma NEFA concentration and apoB secretion rates, others have shown an association between NEFA and apoB turnover rates [52] .
In this study, we cross-sectionally examined a group of diabetic subjects with and without hyperlipidaemia. The results are in keeping with the findings of Kissebah et al. [15] demonstrating increased apoB secretion in both hypertriglyceridaemic and normotriglyceridaemic patients. However, studies using a larger sample size would be required in each group to fully establish the effects of NIDDM on apoB secretion independent of TG concentration. It is possi-ble that normal triglyceride concentrations are maintained in some diabetic patients by enhanced catabolism of VLDL apoB as observed in patients 2 and 6, but our study suggests that in NIDDM, the predominant effect was on secretion of this apolipoprotein. This may reflect the good glycaemic control observed in our patients; poorly controlled diabetic patients have decreased lipoprotein lipase activity, consistent with decreased clearance of VLDL apoB [14] . Although the turnover of VLDL subspecies was not examined, we would have expected a high proportion of VLDL to be large and triglyceriderich as demonstrated in NIDDM patients studied elsewhere [16] . Further support for a predominance of triglyceride-rich VLDL is provided by increased TG/apoB ratios in VLDL of diabetic patients compared with non-diabetic subjects in the present and other studies [17, 18] . Although we did not measure VLDL TG kinetics, several studies have shown that VLDL TG secretion is increased in NIDDM [15] [16] [17] [18] . Therefore, these observations would suggest that hepatic secretion of VLDL TG would have been increased to an even greater extent than that of VLDL apoB in our diabetic patients.
In conclusion, we suggest that in NIDDM insulin resistance increases cholesterol synthesis and that this may stimulate hepatic secretion of VLDL apoB. Further studies are required to confirm the association between VLDL apoB secretion and insulin resistance in NIDDM. For example, the insulin clamp technique at varying insulin concentrations could be used to examine the acute effect of insulin on apoB secretion. The effect of long-term insulin administration, as reported by others [16, 17] , needs to be confirmed by examining apoB secretion in diabetic patients both before and after commencing insulin therapy. If the inhibitory effect of insulin on apoB secretion is clearly demonstrated, it would provide further evidence for an anti-atherogenic action of this hormone [53] .
